{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T21:17:23Z","timestamp":1785014243599,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jaip.2024.03.034","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T18:10:08Z","timestamp":1711476608000},"page":"1132-1136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"12","author":[{"given":"Ryan","family":"Storgard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Markova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2024.03.034_bib1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor\u2013induced toxic effects with shared cancer and tissue antigens in non\u2013small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaip.2024.03.034_bib2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2019.08.045","article-title":"BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors","volume":"82","author":"Ali","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2024.03.034_bib3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.03.034_bib4","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00262-021-02855-1","article-title":"Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors","volume":"70","author":"Tyan","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jaip.2024.03.034_bib6","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2024.03.034_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejim.2021.07.016","article-title":"Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series","volume":"93","author":"Campochiaro","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaip.2024.03.034_bib8","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/bjd.19129","article-title":"Treatment of severe cutaneous adverse reaction with tocilizumab","volume":"183","author":"Hibler","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2024.03.034_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000472","article-title":"Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events","volume":"4","author":"Hoefsmit","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.jaip.2024.03.034_bib10","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2024.03.034_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cup.12666","article-title":"Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy","volume":"43","author":"Schaberg","year":"2016","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.jaip.2024.03.034_bib12","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti\u2013programmed cell death 1 and anti\u2013programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2024.03.034_bib13","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor\u2013related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2024.03.034_bib14","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/annonc\/mdz206","article-title":"The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?","volume":"30","author":"Elkrief","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaip.2024.03.034_bib15","article-title":"Influence of microbiome and antibiotics on the efficacy of immune checkpoint inhibitors","volume":"13","author":"Patel","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2024.03.034_bib16","article-title":"A\u00a0retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution","volume":"30","author":"Masterson","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.jaip.2024.03.034_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/CMR.0000000000000263","article-title":"PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases","volume":"26","author":"Wakade","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaip.2024.03.034_bib18","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/cup.13739","article-title":"Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: a diagnostic pitfall for superficially invasive squamous cell carcinoma","volume":"47","author":"Marques-Piubelli","year":"2020","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.jaip.2024.03.034_bib19","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s00262-020-02797-0","article-title":"Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors","volume":"70","author":"Abdel-Wahab","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jaip.2024.03.034_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","article-title":"Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors","volume":"107","author":"Ali","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaip.2024.03.034_bib21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","article-title":"Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor\u2013induced secondary adrenal insufficiency","volume":"130","author":"Yano","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaip.2024.03.034_bib22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/jdv.17855","article-title":"European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force \u2018dermatology for cancer patients\u2019 position statement","volume":"36","author":"Apalla","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2024.03.034_bib23","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.annonc.2021.02.016","article-title":"IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies","volume":"32","author":"Barrios","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaip.2024.03.034_bib24","article-title":"Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: a case series and review of the literature","volume":"11","author":"Fournier","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.jaip.2024.03.034_bib25","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaad.2009.08.052","article-title":"Antipruritic treatment with systemic \u03bc-opioid receptor antagonists: a review","volume":"63","author":"Phan","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2024.03.034_bib26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamadermatol.2018.4093","article-title":"Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: a systematic review","volume":"155","author":"Ekelem","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2024.03.034_bib27","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","volume":"37","author":"Phillips","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2024.03.034_bib28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2024.03.034_bib29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/bjd\/ljad149","article-title":"Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment","volume":"189","author":"Shipman","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2024.03.034_bib30","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2024.03.034_bib31","first-page":"169","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.jaip.2024.03.034_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14830","article-title":"Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors","volume":"34","author":"Cutroneo","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaip.2024.03.034_bib33","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaad.2020.08.137","article-title":"Immune checkpoint-mediated psoriasis: a multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group","volume":"84","author":"Nikolaou","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2024.03.034_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jdcr.2021.03.029","article-title":"Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma","volume":"11","author":"Glinos","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaip.2024.03.034_bib35","series-title":"The use of interleukin-23 inhibitors to treat immune-related psoriasis induced by immune checkpoint inhibitors and in patients with active cancer: a case series and review of the literature","volume":"11","author":"Fournier","year":"2023"},{"key":"10.1016\/j.jaip.2024.03.034_bib36","article-title":"A\u00a0novel approach to the treatment of pembrolizumab-induced psoriasis exacerbation: a case report","volume":"11","author":"Monsour","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2024.03.034_bib37","doi-asserted-by":"crossref","DOI":"10.5070\/D3268049884","article-title":"Toxic epidermal necrolysis occurring with immune checkpoint inhibitors","volume":"26","author":"Gopee","year":"2020","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaip.2024.03.034_bib38","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaip.2024.03.034_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1346-8138.17039","article-title":"Immune checkpoint inhibitor-induced epidermal necrolysis: a narrative review evaluating demographics, clinical features, and culprit medications","volume":"51","author":"Satoh","year":"2024","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2024.03.034_bib40","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/rheumatology\/key234","article-title":"High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis","volume":"57","author":"Ford","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaip.2024.03.034_bib41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/toxsci\/kfab144","article-title":"Checkpoint inhibition reduces the threshold for drug-specific T-cell priming and increases the incidence of sulfasalazine hypersensitivity","volume":"186","author":"Hammond","year":"2022","journal-title":"Toxicol Sci"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824003271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824003271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T06:11:21Z","timestamp":1724479881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219824003271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2213219824003271"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2024.03.034","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2024.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}